EU/3/12/1093

About

On 24 January 2013, orphan designation (EU/3/12/1093) was granted by the European Commission to Idis Ltd, United Kingdom, for 1,2:5,6-dianhydrogalactitol for the treatment of glioma.

The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.

Key facts

Active substance
1,2:5,6-Dianhydrogalactitol
Disease / condition
Treatment of glioma
Date of first decision
24/01/2013
Outcome
Positive
EU designation number
EU/3/12/1093

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Regulis Consulting Europe Limited
The Black Church
Saint Mary's Place
Dublin 7 DO7 P4AX
Ireland
Tel: +353 1 231 4691
E-mail: admin@regulis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating